Malignant neoplasm of the endometrium
Meaning of malignant neoplasm of the endometrium: For the purposes of this Statement of Principles, malignant neoplasm of the endometrium: (a) means a primary malignant neoplasm arising from the cells of the mucous membrane that line the uterine cavity; and (b) includes; (i) carcinoma in situ and (ii) carcinosarcoma (also known as malignant mesodermal mixed tumour); and (c) excludes; (i) malignant neoplasm of the cervix; (ii) carcinoid tumour; (iii) soft tissue sarcoma of the uterus; (iv) non-Hodgkin's lymphoma; and (v) Hodgkin's lymphoma. (3) While malignant neoplasm of the endometrium attracts ICD-10-AM code C54.1, in applying this Statement of Principles the meaning of malignant neoplasm of the endometrium is that given in subsection (2). (4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.
Reasonable Hypothesis (RH) — Statement of Principles No. 31 of 2025
At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the endometrium or death from malignant neoplasm of the endometrium with the circumstances of a person's relevant service:
- (1)for females aged over 35 years only, having never been pregnant for more than 8 weeks, at the time of clinical onset;
- (2)using oestrogen-only hormone replacement therapy for at least 3 months before clinical onset, and where the use of oestrogen-only hormone replacement therapy has ceased, clinical onset has occurred within 20 years of cessation;
Note: oestrogen-only hormone replacement therapy is defined in the Schedule 1 - Dictionary.
- (3)having cyclical combined hormone replacement therapy where oestrogen is combined with cyclical administration of progesterone for less than 15 days during each treatment cycle, for a continuous period of at least 5 years before clinical onset. Where the use of cyclical combined hormone replacement therapy has ceased, clinical onset has occurred within 10 years of cessation;
- (4)for post-menopausal females only, undergoing treatment with tamoxifen for at least 3 months before clinical onset, and where treatment has ceased, clinical onset has occurred within 20 years of cessation;
- (5)being overweight or obese for at least 5 years within the 20 years before clinical onset;
Note: being overweight or obese is defined in the Schedule 1 - Dictionary.
- (6)having diabetes mellitus for at least 5 years before clinical onset;
- (7)inability to undertake any physical activity greater than 3 METs for at least 10 years within the 30 years before clinical onset;
Note: MET is defined in the Schedule 1 - Dictionary.
- (8)Having undergone treatment with Tibolone for at least 3 months before clinical onset, and where treatment has ceased, clinical onset has occurred within 10 years of cessation;
- (9)inability to obtain appropriate clinical management for malignant neoplasm of the endometrium before clinical worsening;
Aggravation-only factors: the factors in subsection 9(9) apply only to material contribution to, or aggravation of, the condition where it was suffered or contracted before or during (but did not arise out of) the person’s relevant service.
